findmyKOL
Clinical trialNCT00745550CompletedPhase 1/PHASE2Interventional

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

SponsorS*BIOEnrollment55Essential ThrombocythemiaMyelofibrosisMyeloproliferative DisordersPolycythemia Vera
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The study consists of two phases: The first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once daily in subjects with Chronic Idiopathic Myelofibrosis (CIMF) regardless of their JAK2 mutational status. The second portion of the study is a Phase 2 study to define the efficacy and safety profile of single agent SB1518 at the recommended dose in subjects with CIMF.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • Royal Adelaide Hospital

    Adelaide, Australia

United States
  • Mayo Clinic

    Scottsdale, Arizona, United States

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pacritinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Aug 2008
Primary completion
31 Jan 2012
Completion
31 Jan 2012
Last update posted
20 Apr 2012
Registered enrollment
55
Registry id
NCT00745550
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.